Novel platelet products under development for the treatment of thrombocytopenia or acute hemorrhage

Transfus Apher Sci. 2019 Feb;58(1):7-11. doi: 10.1016/j.transci.2018.12.010. Epub 2018 Dec 30.


Controlling hemorrhage has been a focus of survival since man recognized that the loss of blood led to death. Papyri from 1600 BCE describe methods for hemorrhage control including; direct pressure, ligature and the use of sutures. Multiple studies have demonstrated the survival advantage of early transfusion of whole blood or red cells and plasma. The added survival impact of early transfusion of platelets was recently reported in a substudy of the prospective Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial. Early transfusion of platelets demonstrated a statistically significant survival benefit at 24 h and 30 days post-injury. [1] Platelet availability is limited due to the short shelf life (5-7 days) and storage requirements (room temperature with constant agitation). Providing platelets or platelet derived products for prehospital treatment and to rural and some urban hospitals is an unmet medical need. The interest in novel and alternative platelet products has grown over the past decade and the status of novel platelet products is presented herein. Development, approval, and distribution of hemostatically effective approved platelet products for prehospital use and routine stockage in rural and urban centers could significantly increase survival rates in bleeding patients.

Keywords: Bioreactor; Cryopreserved platelets; DMSO; Ex-vivo platelet production; Freeze-Dried platelets; Frozen platelets; Lyophilized platelets; Paraformaldehyde; Trehalose.

Publication types

  • Review

MeSH terms

  • Blood Platelets / cytology
  • Blood Platelets / metabolism*
  • Hemorrhage / therapy*
  • Humans
  • Thrombocytopenia / therapy*